Sudeep Pharma Limited has formally notified stock exchanges about scheduled analyst and institutional investor meetings set for March 23, 2026 in Mumbai. The company submitted this intimation on March 17, 2026, ensuring compliance with regulatory disclosure requirements.

Meeting Details

The pharmaceutical company has organized comprehensive investor engagement sessions with the following specifications:

Regulatory Compliance

Sudeep Pharma Limited filed this disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has specifically emphasized that all discussions during these investor interactions will be based exclusively on publicly available information.

The pharmaceutical company has clearly stated that no unpublished price sensitive information (UPSI) is intended to be discussed during these meetings, ensuring full compliance with regulatory guidelines for investor communications.

Administrative Details

Company Secretary and Compliance Officer Dimple Mehta signed the regulatory filing, noting that meeting schedules may be subject to changes due to exigencies on the part of participants or the company. The document was digitally signed and submitted to both the National Stock Exchange of India Limited and BSE Limited on March 17, 2026 at 15:25:03.

These scheduled investor meetings represent part of Sudeep Pharma Limited's ongoing investor relations activities, providing opportunities for direct engagement between company officials and the investment community while maintaining strict adherence to regulatory disclosure requirements.

Sudeep Pharma Limited has submitted the transcript of its Q3FY26 earnings conference call to stock exchanges, following the company's impressive financial performance and strategic announcements. The earnings call, held on February 9, 2026, provided detailed insights into the company's operational and financial achievements for the third quarter and nine months ended December 31, 2025.

Strong Financial Performance Continues

The earnings call transcript reinforced the company's robust Q3FY26 performance, with management highlighting sustained growth across key metrics. The company's consolidated financial results demonstrated impressive momentum across all business segments.

Management Commentary on Growth Drivers

During the earnings call, Managing Director Sujit Bhayani emphasized the company's 36-year journey and evolution from mineral excipients manufacturer to a diversified portfolio serving over 100 countries. Director Shanil Bhayani provided detailed insights into geographic performance, highlighting strong growth in Asia-Pacific driven by deeper collaboration with leading FMCG and infant nutrition customers.

Business Segment Performance

The earnings call revealed that export business contributed 62% of revenue while domestic business accounted for 38% in Q3FY26. The specialty ingredients segment contributed 41% of revenue, demonstrating strong momentum, while pharma, food and nutrition contributed 59%.

Battery Materials Strategic Initiative

The earnings call provided extensive details on Sudeep Advanced Materials (SAM), the company's battery materials division. Management highlighted progress with 34 customers across the battery value chain, with 70% having approved and validated Sudeep samples. The Dahej facility groundbreaking ceremony was conducted on January 23, 2026, with Phase 1 capacity of 25,000 MT scheduled for early 2027 commissioning.

Capacity Expansion and Future Outlook

CFO Ketan Vyas confirmed that the Nandesari Greenfield facility with 51,200 MT capacity remains on track for March 2026 commissioning. The facility will enable production of higher-value molecules including gluconates, glycinates and citrines. Management expressed confidence in sustaining current growth momentum with stable margin profiles.

Regulatory Compliance

Company Secretary Dimple Mehta submitted the earnings call transcript to NSE (Scrip Symbol: SUDEEPPHRM) and BSE (Scrip Code: 544619) on February 12, 2026, under Regulation 30 of SEBI LODR Regulations. The transcript is also available on the company's website at https://www.sudeeppharma.com/ .